Literature DB >> 15374954

Genomic and expression profiling of chromosome 17 in breast cancer reveals complex patterns of alterations and novel candidate genes.

Béatrice Orsetti1, Mélanie Nugoli, Nathalie Cervera, Laurence Lasorsa, Paul Chuchana, Lisa Ursule, Catherine Nguyen, Richard Redon, Stanislas du Manoir, Carmen Rodriguez, Charles Theillet.   

Abstract

Chromosome 17 is severely rearranged in breast cancer. Whereas the short arm undergoes frequent losses, the long arm harbors complex combinations of gains and losses. In this work we present a comprehensive study of quantitative anomalies at chromosome 17 by genomic array-comparative genomic hybridization and of associated RNA expression changes by cDNA arrays. We built a genomic array covering the entire chromosome at an average density of 1 clone per 0.5 Mb, and patterns of gains and losses were characterized in 30 breast cancer cell lines and 22 primary tumors. Genomic profiles indicated severe rearrangements. Compiling data from all samples, we subdivided chromosome 17 into 13 consensus segments: 4 regions showing mainly losses, 6 regions showing mainly gains, and 3 regions showing either gains or losses. Within these segments, smallest regions of overlap were defined (17 for gains and 16 for losses). Expression profiles were analyzed by means of cDNA arrays comprising 358 known genes at 17q. Comparison of expression changes with quantitative anomalies revealed that about half of the genes were consistently affected by copy number changes. We identified 85 genes overexpressed when gained (39 of which mapped within the smallest regions of overlap), 67 genes underexpressed when lost (32 of which mapped to minimal intervals of losses), and, interestingly, 32 genes showing reduced expression when gained. Candidate genes identified in this study belong to very diverse functional groups, and a number of them are novel candidates.

Entities:  

Mesh:

Year:  2004        PMID: 15374954     DOI: 10.1158/0008-5472.CAN-04-0756

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  29 in total

1.  Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction.

Authors:  Silvia Bea; Andreas Zettl; George Wright; Itziar Salaverria; Philipp Jehn; Victor Moreno; Christof Burek; German Ott; Xavier Puig; Liming Yang; Armando Lopez-Guillermo; Wing C Chan; Timothy C Greiner; Dennis D Weisenburger; James O Armitage; Randy D Gascoyne; Joseph M Connors; Thomas M Grogan; Rita Braziel; Richard I Fisher; Erlend B Smeland; Stein Kvaloy; Harald Holte; Jan Delabie; Richard Simon; John Powell; Wyndham H Wilson; Elaine S Jaffe; Emili Montserrat; Hans-Konrad Muller-Hermelink; Louis M Staudt; Elias Campo; Andreas Rosenwald
Journal:  Blood       Date:  2005-07-26       Impact factor: 22.113

2.  The adaptor protein Tom1L1 is a negative regulator of Src mitogenic signaling induced by growth factors.

Authors:  Mélanie Franco; Olivia Furstoss; Valérie Simon; Chrsitine Benistant; Wan Jing Hong; Serge Roche
Journal:  Mol Cell Biol       Date:  2006-03       Impact factor: 4.272

3.  Pathway-BasedFeature Selection Algorithm for Cancer Microarray Data.

Authors:  Nirmalya Bandyopadhyay; Tamer Kahveci; Steve Goodison; Y Sun; Sanjay Ranka
Journal:  Adv Bioinformatics       Date:  2010-03-03

4.  ZNF750 represses breast cancer invasion via epigenetic control of prometastatic genes.

Authors:  Matteo Cassandri; Alessio Butera; Ivano Amelio; Anna Maria Lena; Manuela Montanaro; Alessandro Mauriello; Lucia Anemona; Eleonora Candi; Richard A Knight; Massimiliano Agostini; Gerry Melino
Journal:  Oncogene       Date:  2020-04-20       Impact factor: 9.867

Review 5.  Wip1 phosphatase in breast cancer.

Authors:  A Emelyanov; D V Bulavin
Journal:  Oncogene       Date:  2014-11-10       Impact factor: 9.867

6.  Lack of independent prognostic and predictive value of centromere 17 copy number changes in breast cancer patients with known HER2 and TOP2A status.

Authors:  Kirsten Vang Nielsen; Bent Ejlertsen; Susanne Møller; Maj-Britt Jensen; Eva Balslev; Sven Müller; Ann Knoop; Henning T Mouridsen
Journal:  Mol Oncol       Date:  2011-11-26       Impact factor: 6.603

7.  A chromosome-centric human proteome project (C-HPP) to characterize the sets of proteins encoded in chromosome 17.

Authors:  Suli Liu; Hogune Im; Amos Bairoch; Massimo Cristofanilli; Rui Chen; Eric W Deutsch; Stephen Dalton; David Fenyo; Susan Fanayan; Chris Gates; Pascale Gaudet; Marina Hincapie; Samir Hanash; Hoguen Kim; Seul-Ki Jeong; Emma Lundberg; George Mias; Rajasree Menon; Zhaomei Mu; Edouard Nice; Young-Ki Paik; Mathias Uhlen; Lance Wells; Shiaw-Lin Wu; Fangfei Yan; Fan Zhang; Yue Zhang; Michael Snyder; Gilbert S Omenn; Ronald C Beavis; William S Hancock
Journal:  J Proteome Res       Date:  2012-12-21       Impact factor: 4.466

8.  TOM1L is involved in a novel signaling pathway important for the IL-2 production in Jurkat T cells stimulated by CD3/CD28 co-ligation.

Authors:  Ahmed Elmarghani; Hanan Abuabaid; Peter Kjellen
Journal:  Mediators Inflamm       Date:  2010-02-21       Impact factor: 4.711

9.  Vesicular trafficking regulators are new players in breast cancer progression: Role of TOM1L1 in ERBB2-dependent invasion.

Authors:  Clément Chevalier; Serge Roche; Christine Bénistant
Journal:  Mol Cell Oncol       Date:  2016-04-28

10.  Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets.

Authors:  N Turner; M B Lambros; H M Horlings; A Pearson; R Sharpe; R Natrajan; F C Geyer; M van Kouwenhove; B Kreike; A Mackay; A Ashworth; M J van de Vijver; J S Reis-Filho
Journal:  Oncogene       Date:  2010-01-18       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.